Australia markets closed

Syros Pharmaceuticals, Inc. (SYRS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.2600+0.0400 (+0.95%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.2200
Open4.2000
Bid0.0000 x 800
Ask0.0000 x 1300
Day's range4.1200 - 4.3700
52-week range4.0000 - 15.6500
Volume327,701
Avg. volume513,362
Market cap263.825M
Beta (5Y monthly)1.92
PE ratio (TTM)N/A
EPS (TTM)-1.5780
Earnings date03 Nov 2021 - 08 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est17.14
  • Business Wire

    Syros Reports Inducement Grant to Chief Financial Officer under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., October 13, 2021--Syros Pharmaceuticals (Nasdaq: SYRS) ("Syros" or the "Company"), a leader in the development of medicines that control the expression of genes, today announced the grant of an inducement stock option award to Jason Haas, the Company’s recently hired Chief Financial Officer, in accordance with Mr. Haas’s employment offer letter. The grant was approved by the Company’s Board of Directors and was made as a material inducement to Mr. Haas’s acceptance of employmen

  • Business Wire

    Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer

    CAMBRIDGE, Mass., October 12, 2021--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Jason Haas as Chief Financial Officer. Mr. Haas brings more than 25 years of healthcare investment banking and corporate finance experience to Syros.

  • Business Wire

    Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia

    CAMBRIDGE, Mass., September 29, 2021--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been dosed in the dose confirmation study of SY-2101, a novel oral form of arsenic trioxide (ATO). The trial will evaluate the pharmacokinetics (PK), safety, and tolerability of SY-2101 to confirm the optimal dose to advance into a planned Phase 3 clinical trial in newly diagnosed acute promyelocytic l